Heart Failure
RSSArticles
-
Iron Therapy for Acute Heart Failure
Giving intravenous ferric carboxymaltose to stabilized post-acute heart failure patients with iron deficiency improved quality of life vs. placebo-treated patients within four weeks, which persisted during subsequent therapy for up to 24 weeks.
-
Slow, Steady, and Synchronized Wins the Race
In patients with atrial fibrillation and heart failure, definitive rate control via atrioventricular junction ablation and biventricular pacing resulted in a significant reduction in all-cause mortality vs. pharmacologic rate control.
-
Early Physical Rehabilitation in Acutely Hospitalized Heart Failure Patients
A tailored, progressive physical rehabilitation program started in the hospital and continued for three months in older, relatively frail acute heart failure admissions resulted in significantly improved physical function vs. usual care but did not reduce six-month readmission rates. -
Alcohol Consumption and Atrial Fibrillation
An analysis of the UK Biobank database revealed low levels of alcohol consumption, especially with wine and spirits, is associated with the lowest incidence of atrial fibrillation. -
Iron Therapy for Acute Heart Failure
Giving intravenous ferric carboxymaltose to stabilized post-acute heart failure patients with iron deficiency improved quality of life vs. placebo-treated patients within four weeks, which persisted during subsequent therapy for up to 24 weeks. -
AAP Recommends Screening All Children for Heart Problems
Around 2,000 Americans younger than age 25 die each year because of sudden cardiac death. -
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy. -
Is Empagliflozin Safe in Combination with a Neprilysin Inhibitor for Heart Failure?
A prespecified subgroup analysis of heart failure patients with reduced ejection fraction who were on neprilysin inhibitors before empagliflozin was administered (vs. those not on neprilysin inhibitors) showed the reduction in mortality and hospital admissions for heart failure was not attenuated by concurrent neprilysin use.
-
Low BNP Levels in Up to 16% of Heart Failure Patients
In patients with clinical heart failure and low B-type natriuretic peptide levels, the authors found these patients usually are young and obese, with higher ejection fraction and better renal function.
-
Low BNP Levels in Up to 16% of Heart Failure Patients
In patients with clinical heart failure and low B-type natriuretic peptide levels, the authors found these patients usually are young and obese, with higher ejection fraction and better renal function.